ワクチンアジュバントの市場規模、シェア、成長分析：製品別、アジュバントの種類別、投与経路別、疾患タイプ別、用途別、ワクチンの種類別、地域別 - 産業予測 2025～2032年

ワクチンアジュバントの世界市場規模は2023年に6億7,010万米ドルと評価され、2024年の7億1,171万米ドルから2032年には11億5,247万米ドルに成長し、予測期間（2025～2032年）のCAGRは6.21%で推移する見通しです。

ワクチンアジュバント市場は、新興および再興病原体を含む感染症の罹患率の上昇によって大きな成長を遂げています。このような感染症の急増により、効果的な予防接種の需要が高まっており、アジュバントは予防接種の効果を高める上で重要な要素となっています。特にCOVID-19以降、予防ヘルスケアに世界的に焦点が当てられる中、疾病予防の主要な戦略として予防接種がますます重視されるようになっています。アジュバントは、抗原が注射部位に存在する時間を延長し、免疫細胞を活性化し、免疫反応を調節することにより、最終的にはより強力で持続的な免疫を育むという極めて重要な役割を担っています。研究開発によって多様な疾患をターゲットとする革新的なワクチンが生み出されるにつれ、ワクチンアジュバント市場は継続的に拡大し、豊富な成長機会を提供する態勢が整っています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• 特許分析

ワクチンアジュバント市場規模：製品別

• 市場概要
• エマルジョンアジュバント
• サポニンベースのアジュバント
• 微粒子ベースのアジュバント
• その他のアジュバント

ワクチンアジュバント市場規模：アジュバントの種類別

• 市場概要
• 有機アジュバント
• 無機アジュバント

ワクチンアジュバント市場規模：投与経路別

• 市場概要
• 筋肉内
• 皮下
• その他の投与経路

ワクチンアジュバント市場規模：疾患タイプ別

• 市場概要
• 感染症
• がん
• その他の病気

ワクチンアジュバント市場規模：用途別

• 市場概要
• 調査アプリケーション
• 商用アプリケーション

ワクチンアジュバント市場規模：ワクチンの種類別

• 市場概要
• ヒト用ワクチン
  • 感染症
  • 治療用
• 獣医用ワクチン
  • ペット動物
  • 家畜
• その他の動物

ワクチンアジュバント市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• GSK plc（UK）
• SEPPIC（France）
• Croda International Plc（UK）
• SPI Pharma（USA）
• Agenus Inc.（USA）
• Phibro Animal Health Corporation（USA）
• Aurorium（USA）
• Dynavax Technologies Corporation（USA）
• Novavax Inc.（USA）
• Merck KGaA（Germany）
• Vaxine Pty Ltd.（Australia）
• Hawaii Biotech Inc.（USA）
• CSL Limited（Australia）
• OZ Biosciences（France）
• InvivoGen（USA）
• Allergy Therapeutics（UK）
• EuBiologics Co., Ltd.（South Korea）
• Pacific GeneTech Limited（USA）
• Riboxx GmbH（Germany）
• Oncovir, Inc.（USA）

結論と提言

Global Vaccine Adjuvants Market size was valued at USD 670.1 million in 2023 and is poised to grow from USD 711.71 million in 2024 to USD 1152.47 million by 2032, growing at a CAGR of 6.21% during the forecast period (2025-2032).

The vaccine adjuvants market is experiencing significant growth driven by the rising incidence of infectious diseases, including both newly emerging and reemerging pathogens. This surge in infectious diseases has heightened the demand for effective vaccinations, positioning adjuvants as critical components in enhancing immunization efficacy. With a global focus on preventive healthcare, particularly post-COVID-19, there is an increasing emphasis on immunization as a primary strategy for disease prevention. Adjuvants play a pivotal role by prolonging antigen presence at the injection site, activating immune cells, and modulating the immune response, which ultimately fosters a stronger and more sustained immunity. As research and development yield innovative vaccines targeting diverse diseases, the market for vaccine adjuvants is poised for continued expansion, presenting abundant opportunities for growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Adjuvants market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Adjuvants Market Segments Analysis

Global Vaccine Adjuvants Market is segmented by Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type and region. Based on Product, the market is segmented into Emulsion Adjuvants, Pathogen Components, Saponin-Based Adjuvants, Particulate-Based Adjuvants and Other Adjuvants. Based on Adjuvant Type, the market is segmented into Organic Adjuvants and Inorganic Adjuvants. Based on Route Of Administration, the market is segmented into Intramuscular, Subcutaneous and Other Routes of Administration. Based on Disease Type, the market is segmented into Infectious Diseases, Cancer and Other Diseases. Based on Application, the market is segmented into Research Applications and Commercial Applications. Based on Vaccine Type, the market is segmented into Human Vaccines, Veterinary Vaccines and Other Animals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Adjuvants Market

The COVID-19 pandemic has heightened global health concerns, leading to a significant rise in the demand for vaccinations, particularly those incorporating adjuvants. This trend is driven by the necessity for more effective vaccination strategies to combat a variety of infectious diseases and new emerging pathogens, which are crucial for maintaining community immunity. Consequently, vaccine manufacturers are actively seeking innovative methods to boost the potency of their vaccinations, investing in cutting-edge adjuvant technologies to enhance their effectiveness. This ongoing pursuit for improved vaccination solutions is a key driver in the Global Vaccine Adjuvants market.

Restraints in the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market faces significant constraints due to stringent regulatory barriers that impact the licensing of these products. These strict regulations can lead to delays in the market entry of new adjuvants, ultimately increasing costs for manufacturers and creating additional challenges for business growth. Navigating the complex regulatory landscape often requires substantial resources, making it particularly difficult for smaller companies to comply with safety standards and establish a foothold in the market. This regulatory burden poses a notable hurdle, potentially stifling innovation and competition in the vaccine adjuvant sector.

Market Trends of the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market is witnessing a significant trend towards personalized immunization plans, marking a transformative shift in vaccination strategies. As researchers increasingly focus on tailoring vaccines to individual patient profiles-considering genetic variations and specific immune responses-this approach aims to enhance vaccine efficacy and patient outcomes. By employing targeted adjuvants designed for diverse patient populations, the market is expected to drive innovation and demand for customized solutions. This evolution reflects a broader trend of precision medicine in immunization, indicating a growing commitment to improving public health through more effective and personalized vaccination strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Vaccine Adjuvants Market Size by Product & CAGR (2025-2032)

• Market Overview
• Emulsion Adjuvants
• Saponin-Based Adjuvants
• Particulate-Based Adjuvants
• Other Adjuvants

Global Vaccine Adjuvants Market Size by Adjuvant Type & CAGR (2025-2032)

• Market Overview
• Organic Adjuvants
• Inorganic Adjuvants
• Global Vaccine Adjuvants Market Size by Route Of Administration & CAGR (2025-2032)
• Market Overview
• Intramuscular
• Subcutaneous
• Other Routes of Administration

Global Vaccine Adjuvants Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Infectious Diseases
• Cancer
• Other Diseases

Global Vaccine Adjuvants Market Size by Application & CAGR (2025-2032)

• Market Overview
• Research Applications
• Commercial Applications

Global Vaccine Adjuvants Market Size by Vaccine Type & CAGR (2025-2032)

• Market Overview
• Human Vaccines
  • Infectious Diseases
  • Therapeutic
• Veterinary Vaccines
  • Companion Animals
  • Livestock Animals
• Other Animals

Global Vaccine Adjuvants Market Size & CAGR (2025-2032)

• North America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • US
  • Canada
• Europe (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SEPPIC (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Croda International Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SPI Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurorium (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxine Pty Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hawaii Biotech Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OZ Biosciences (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InvivoGen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergy Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EuBiologics Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific GeneTech Limited (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Riboxx GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncovir, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations